Merck’s New Drugs Offset Patent Losses

The company’s strong entrenchment in the emerging immuno-oncology area should strengthen its competitive position with drugs that carry strong pricing power. After facing a deteriorating moat trend over the past five years, Merck’s competitive advantages … http://news.morningstar.com/articlenet/article.aspx?id=715870